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Abstract
Background: Parkinson’s disease (PD) is a complex, age-related neurodegenerative disorder of largely unknown
etiology. PD is strongly associated with mitochondrial respiratory dysfunction, which can lead to epigenetic
dysregulation and specifically altered histone acetylation. Nevertheless, and despite the emerging role of
epigenetics in age-related brain disorders, the question of whether aberrant histone acetylation is involved in PD
remains unresolved.
Methods: We studied fresh-frozen brain tissue from two independent cohorts of individuals with idiopathic PD
(n = 28) and neurologically healthy controls (n = 21). We performed comprehensive immunoblotting to identify
histone sites with altered acetylation levels in PD, followed by chromatin immunoprecipitation sequencing (ChIP-
seq). RNA sequencing data from the same individuals was used to assess the impact of altered histone acetylation
on gene expression.
Results: Immunoblotting analyses revealed increased acetylation at several histone sites in PD, with the most
prominent change observed for H3K27, a marker of active promoters and enhancers. ChIP-seq analysis further
indicated that H3K27 hyperacetylation in the PD brain is a genome-wide phenomenon with a strong predilection
for genes implicated in the disease, including SNCA, PARK7, PRKN and MAPT. Integration of the ChIP-seq with
transcriptomic data from the same individuals revealed that the correlation between promoter H3K27 acetylation
and gene expression is attenuated in PD patients, suggesting that H3K27 acetylation may be decoupled from
transcription in the PD brain. Strikingly, this decoupling was most pronounced among nuclear-encoded
mitochondrial genes, corroborating the notion that impaired crosstalk between the nucleus and mitochondria is
involved in the pathogenesis of PD. Our findings independently replicated in the two cohorts.
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Conclusions: Our findings strongly suggest that aberrant histone acetylation and altered transcriptional regulation
are involved in the pathophysiology of PD. We demonstrate that PD-associated genes are particularly prone to
epigenetic dysregulation and identify novel epigenetic signatures associated with the disease.
Keywords: H3K27, Epigenetics, Neurodegeneration, ChIP-seq, Sirtuin, Mitochondria, Gene expression
Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, affecting ~ 1.8% of the
population above the age of 65 years [1]. The neuro-
pathological hallmark of PD is the progressive loss of
dopaminergic neurons in the substantia nigra pars com-
pacta (SNc) in the presence of α-synuclein-positive in-
clusions termed Lewy pathology. Additional
neurodegenerative changes occur in multiple regions of
the nervous system, including several brainstem nuclei,
the olfactory bulb, hippocampus, amygdala and the neo-
cortex, as well as the autonomic and enteric nervous sys-
tems [2].
The etiology of PD remains largely unknown. While
monogenic forms of PD exist, they are rare, generally ac-
counting for less than 5–10% of all cases in most popu-
lations. The vast majority of patients have “idiopathic
PD”, which is of complex etiology [3]. Genome-wide as-
sociation studies (GWAS) have identified multiple risk
loci associated with idiopathic PD. These make a rela-
tively small collective contribution to the disease risk,
however, and have not been linked to specific molecular
mechanisms that could be targeted therapeutically [4].
Epigenetic modifications, such as DNA methylation
and histone acetylation, modulate gene expression with-
out altering the underlying DNA sequence. Dysregula-
tion of histone acetylation has been previously linked to
aging [5] and neurodegeneration [6] and changes in his-
tone acetylation at specific genomic regions have been
reported in Alzheimer’s disease [7, 8]. Despite the emer-
ging role of epigenetics in age-related brain disorders,
only a few small-scale studies of histone acetylation in
PD have been reported to date, providing inconclusive
results [9–11]. Moreover, the genomic landscape of his-
tone acetylation in PD has never been assessed.
Here, we report the first genome-wide study of histone
acetylation in the PD brain, based on a population-based co-
hort from the Norwegian Park West study (PW) [12]. Our
findings replicate in an independent cohort of subjects from
the Netherlands Brain Bank (NBB) and reveal genome-wide
dysregulation of H3K27 acetylation in the PD brain.
Methods
Cohorts and tissue
Brains were collected at autopsy and split sagittally along
the corpus callosum. One hemisphere was fixed whole
in formaldehyde for ~ 2 weeks, and the other coronally
sectioned and snap-frozen in liquid nitrogen. Samples
from the frozen hemisphere were included in this study.
Prefrontal cortex (Brodmann area 9) was obtained from
two independent cohorts. The discovery cohort (Park-
West, or PW cohort) comprised individuals with idio-
pathic PD (n = 17) from the ParkWest study, a
prospective population-based cohort which has been de-
scribed in detail [12], and neurologically healthy controls
(n = 15) from the Neuromics Biobank for Aging and
Neurodegeneration. For a subset of the PW cohort (PD:
n = 7, Control: n = 7), tissue samples from the striatum
(putamen) and cerebellar cortex were also included. All
individuals of the PW cohort had undergone whole-
exome sequencing [13] and pathogenic mutations in
genes implicated in Mendelian PD and other monogenic
neurological disorders had been ruled-out. The replica-
tion cohort comprised individuals with idiopathic PD
(n = 10) and neurologically healthy controls (n = 11) of
Dutch origin, from the Netherlands Brain Bank (https://
www.brainbank.nl/). Demographic information and ex-
perimental allocation of all samples is shown in Supple-
mentary Table S1. For each experiment, there were no
significant differences for sex, age, or postmortem inter-
val (PMI) between the compared groups. A complete list
of the medication used by the individuals with PD dur-
ing at least the last 12 months before death can be found
in Supplementary Table S1. Individuals with PD fulfilled
the National Institute of Neurological Disorders and
Stroke [14] and the U.K. PD Society Brain Bank [15]
diagnostic criteria for PD at their final visit. All cases
showed neuropathological changes consistent with PD
(Supplementary Table S1).
Immunoblotting
Three independently dissected samples of brain tissue
(replicates) were analyzed from each individual. Immu-
noblots were repeated at least 2 times for each marker.
To normalize the histone acetylation signal to histone
quantity, each acetylation blot was stripped twice.
Complete stripping was confirmed by incubation of the
membranes with secondary antibodies only and ECL. To
exclude potential bias due to incomplete stripping, we
performed additional experiments where acetylated and
total histone markers for each histone modification were
assessed in parallel on different blots. To estimate the
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acetylated fraction of each histone marker, we calculated
the signal ratio of acetylated marker to total histone pro-
tein. This ratio is referred to as the “acetylation fraction”
for each histone marker. Detailed description is provided
in the Supplementary material, methods section. Com-
parison of immunoblot densitometric values between
groups was performed using linear regression for pan-
acetylation and linear mixed-models for all other
markers. Linear mixed-models analysis was chosen in
order to account for intraindividual random variability.
Subjects were specified as random effects and disease
state, sex, age of death, PMI and oligodendrocyte MSP
were used as fixed effects. The error distribution was as-
sumed normal, and solution to the mixed models was
obtained using the maximum likelihood estimation
method. The mixed-models analyses were implemented
in SPSS version 22.0.0.
Chromatin Immunoprecipitation sequencing (ChIP-seq)
Approximately 200 mg of frozen PFC tissue per sample
was used for ChIP-seq. Briefly, the tissue was crosslinked
using formaldehyde, lysed using a Dounce homogenizer
and sonicated to obtained chromatin fragment of 300–
500 bp. Chromatin was immunoprecipitated using an
antibody against acetylated H3K27. Protein-DNA com-
plexes were recovered using protein A agarose beads,
de-crosslinked and DNA was purified by phenol-
chloroform extraction and ethanol precipitation. Follow-
ing quantitative PCR, libraries were built and sequenced
on Illumina’s NextSeq 500 (75 base pair reads, single
end). Detailed description is provided in the Supplemen-
tary material, methods section.
ChIP-seq quality control and filtering
The analysis of the ChIP-seq data was performed in
accordance with ENCODE ChIP-seq standards
https://www.encodeproject.org/chip-seq/histone/
#standards. Raw FASTQ files were trimmed using
Trimmomatic version 0.38 [16] with options ILLUMI-
NACLIP:TruSeq2-SE.fa:2:30:10 LEADING:3 TRAILI
NG:3
SLIDINGWINDOW:4:15 MINLEN:25. Assessment of
FASTQ files was carried out with FastQC version 0.11.8
[https://www.bioinformatics.babraham.ac.uk/projects/
fastqc] before and after trimming. Reads were aligned to
the GRCh37 human genome using bwa version 0.7.17
[17]. Reads with mapping quality < 30 were discarded
using samtools version 1.9 [https://www.htslib.org/] and
duplicated reads removed using MarkDuplicates from
Picard Tools version 2.18.27 [https://broadinstitute.
github.io/picard/]. BAM files were converted into BED
files and sorted.
Peak calling and read counting
Peak calling procedure was carried out in two comple-
mentary approaches: 1) Per group (PD or controls): the
peaks are called separately for each group, aggregating
the relevant samples and inputs. While this approach is
not optimal for differential peak calling analysis as it re-
quires harmonization of peaks between the two groups,
it can be used to compare the total genome coverage as
well as unique H3K27ac genomic regions in each group.
2) All samples combined: the peaks are called by aggre-
gating all samples and input controls. This approach
does not allow identification of unique genomic regions
however, it provides a better identification of consensus
peaks, and thus, was used for differential peak analysis.
The resulting peak-sets were filtered using the ENCODE
black listed regions and only peaks within canonical
chromosomes were kept for downstream analyses.
Sample-specific enrichment on the identified peaks was
performed using featureCounts version 1.6.4 [18] with
default parameters. For both the individual group and all
samples combined approaches, peaks with non-adjusted
p-value > 10− 7 were excluded from the analysis. Reads
inside peaks (RiP) were quantified using “featureCounts”
program from the “subread” package v2.0.0. Additional
details are provided in the Supplementary material,
methods section.
Calculation of marker site profiles (MSP)
In order to identify brain cell-type specific H3K27ac re-
gions we first analyzed H3K27ac ChIP-seq data from
NeuN+ and NeuN− brain cells [19]. Cell-type based
broadPeaks (CellType_peak-set), count matrixes and
metadata files were downloaded from https://www.
synapse.org/#!Synapse:syn4566010. Differential regions
between NeuN+ and NeuN− cells were calculated using
“DESeq2” R package [20], including chromatin amount,
library batch, sex, hemisphere, age and pH as covariates
in the model. Peaks were defined as cell-type specific dif-
ferentially acetylated regions (DARs) if they met the fol-
lowing criteria: a) |fold change| > 4 and b) mean count >
1000. Peaks were annotated to all genes for which they
intersected a region between 5 kb upstream from their
transcription start site (TSS) to the end of their 5’UTR
using “annotatr” R package [21], based on UCSC hg19
genome assembly. Genes with DARs were then iter-
sected with expression-based cortical marker gene lists
based on NeuroExpresso database [22]. The DARs were
next reassigned to specific cell-types if they were anno-
tated to genes defined as cell-type specific based on
NeuroExpresso. For example, all DARs annotated to
MBP, defined as oligodendrocyte marker gene based on
NeuroExpresso, were defined as oligodendrocyte marker
sites (MSS). In the next step, we quantified the reads
from our samples in the CellType_peak-set. The
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corresponding RiP were then converted to counts per
million (CPM) and transformed to log2(CPM + 1). Next,
for each cell-type specific MSS, we performed principal
component analysis based on the relevant peaks as de-
scribed in [22]. Marker Site Profiles (MSP) were defined
as the scores of the samples in the first principal compo-
nent, transformed to [0,1] range for visualization pur-
poses. Detailed description of the analysis is provided in
the Supplementary material, methods section.
Identification of differentially acetylated regions
Differential peak analysis was performed using “nbinom-
WaldTest” function from “DESeq2” R package. Disper-
sions were calculated by using “estimateDispertions”
function from “DESeq2” R package, by setting the fit-
Type parameter to “local”. Normalization factors calcu-
lated by the “estimateSizeFactors” function were
replaced with the housekeeping normalization factor
based on our manually selected housekeeping gene set
(ACTB, GAPDH, UBC). Peak significance was deter-
mined using DESeq2 “results” function, setting the cutoff
for adjusted p-value to 0.05, and independentFiltering =
T. Detailed description of the analysis is provided in the
Supplementary material, methods section.
Association of H3K27 hyperacetylation with p300 and
non-SIRT1 HDAC binding
ChIP-seq data (wgEncodeRegTfbsClusteredV3.bed) was
obtained from the Encyclopedia of DNA Elements (EN-
CODE) project [23]. The data was available for p300 and
the following HDACs: HDAC1, HDAC2, HDAC6,
HDAC8 and SIRT6 We first quantified the number of
binding sites for each protein in our peaks using the
“findOverlaps” function from the “GenomicRanges” R
package [24]. For each peak, the HDAC binding sites
were then summed up to represent the non-SIRT1
HDAC_binding. Peaks that had no binding sites for ei-
ther of the proteins were excluded from downstream
analyses. For the gene level analysis, the number of bind-
ing sites in each peak was collapsed to a gene level.
Difference between DARs and non DARs was assessed
by comparing the value of log p300Bindingþ0:01HDACbindingþ0:01 of the peaks
using Kolmogorov-Smirnov test (all genes) or Wilcox-
son’s rank sum test (PD_implicated genes) using “ks.test”
and “wilcox.test” functions from R “stats” package. For
linear model, we first obtained one-sided hyperacetyla-
tion p-value (phyper) for each peak as followed: Phyper
¼ 1−p=2; LFC < 0
p=2; LFC≥0

. The association of hyperacetyla-
tion with p300_binding and HDAC binding was then
assessed by the linear model: − log 10(phyper)~p300bind-
ing +HDACbinding + PDgene where PDgene indicates
whether a peak is annotated to PD_implicated gene or
not.
Association of PD_implicated genes and EGL with altered
H3K27 acetylation
Effective gene length (EGL) was defined as sum of length
of all regions annotated to the gene (including 1Kb up-
stream to TSS). We assessed the association between al-
tered H3K27 acetylation defined as -log10(metaP) with
being annotated to a PD_implicated gene (PDgene), EGL
and the total number of common regions aligned to the
gene using a linear model. The total number of common
regions in a gene was included as a covariate in the
model. Namely, for a common region i, annotated to
gene j, the -log (metaP) value was modeled as: − log
10(metaPij)~PDgenej + log 10(EGLj) + ∑ CommonRe-
gionsj. For the analysis was performed in each cohort
separately, metaP was replaced with cohort-specific p-
value, and the total number of common regions was re-
placed with the total number of regions (peaks) anno-
tated to the gene in the cohort-specific peak-set.
Transcription factor enrichment analysis
The genomic sequence of hypo- and hyper-acetylated re-
gions were repeat masked, and the enrichment of transcrip-
tion factor binding motifs (TFBM) was assessed using the
Analysis Motif of Enrichment (AME tool) [25] from the
MEME Suite [26] v5.3.2, by setting the fraction of max-
imum log-odds to 0.75, and using human (HOCOMOCO
v11) motif database [27]. The enrichment was assessed
using Fisher’s exact test, with length-matched non-
differentially acetylated regions set as the background.
RNA-seq analysis
Total RNA was extracted from prefrontal cortex tissue
homogenate for all samples for which ChIP-seq was per-
formed and sequenced following ribosomal RNA deple-
tion A detailed description of the RNA-seq analysis is
provided in the Supplementary material, methods sec-
tion and is reported elsewhere [28]. Relative cell abun-
dance was estimated using cell-type specific marker
genes, as previously described [22, 29]. Since significant
group effect was found for oligodendrocytes and micro-
glia estimates in PW (Wilcoxon’s p = 2.6 × 10− 4) and
NBB (Wilcoxon’s p = 0.009) cohorts respectively, these
cell types were included at covariates in the analysis of
both cohorts. Count matrix and the code necessary to
reproduce these results are available on https://git.app.
uib.no/neuromics/cell-composition-rna-pd.
Promoter H3K27ac - expression correlation
ChIP-seq and RNA-seq counts were first adjusted to the
relevant covariates (age, sex, PMI, batch, oligodendro-
cyte estimates and microglia estimates). The adjustment
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was done by re-fitting the counts using the coefficients
calculated by DESeq2 R function with adjusted model
matrix in which categorical covariates were set to 0, and
the continuous covariates to the mean of the original
values. Next, for each gene, Pearson’s correlation be-
tween the adjusted ChIP-seq/RNA-seq seq counts was
computed using “cor.test” R function, in each group
(controls or PD subjects) separately. Only peaks anno-
tated to promoter regions of the genes were included in
the analysis. When multiple promoter peaks were de-
fined for a gene, the correlation was calculated for each
promoter separately, and the highest correlation was
kept. This step was performed independently for each
group. Since not all genes are expected to exhibit a good
correspondence between promoter H3K27ac state and
expression level due to existence of multiple levels of
regulation, we compared the distribution of correlations
in each group for different thresholds of absolute correl-
ation in either of the groups (e.g., cor > |0.1| means that
only genes with absolute correlation > 0.1 in at least one
of the groups are included in the analysis). Group com-
parison was performed using Wilcoxon rank sum test,
using “wilcox.test” function from R “stats” function.
Functional enrichment analysis was performed using the
gene score resampling method implemented in the ermi-
neR package version 1.0.1 [30], an R wrapper package
for ermineJ [31], setting the value of “BigIsBetter” to
FALSE, with the complete Gene Ontology (GO) data-
base annotation [32]. For the enrichment of genes based
on the decoupling levels, gene scores were defined as
ΔCor = CorPD −CorControl. For enrichment of genes based
on the lowest correlation in PD group, gene scored were
defined as the correlation values in the PD group.
Data and code availability
The R code necessary to reproduce the results presented
in the paper is available on https://github.com/ltoker/
ChIPseqPD. Raw counts for the ChIP-seq analyses are
available in the same repository (https://github.com/
ltoker/ChIPseqPD/tree/master/data). UCSC genome
browser tracks showing the H3K27ac peak-sets based on
PW and NBB cohorts can be accessed at https://
genome-euro.ucsc.edu/s/ltoker/H3K27ChIP_PD. Add-
itional R code to reproduce the RNA-seq analyses is
available on https://git.app.uib.no/neuromics/cell-
composition-rna-pd. The corresponding raw data counts
are included in the repository (https://git.app.uib.no/
neuromics/cell-composition-rna-pd/tree/master/Data).
Results
Increased histone acetylation and histone protein levels
in the PD brain
We first assessed global protein acetylation in the pre-
frontal cortex (PFC) of 13 individuals with PD and 13
demographically matched controls from the PW cohort
by immunoblot analysis using an antibody against acety-
lated lysine (Fig. 1a, Supplementary Table S1). We con-
centrated on PFC because, while this area is typically
affected in PD [33–35], it is generally less confounded
by altered cell composition due to neurodegeneration
and neuroinflammation [2]. Linear regression analysis of
the densitometric measurements, adjusted for age, sex
and PMI, indicated an increased acetylation signal at ~
17 kDa, consistent with the molecular weight of core his-
tone proteins (p = 0.014, Fig. 1a).
To identify histone sites contributing to the hyperace-
tylation observed in our samples and select a specific site
for downstream analyses, we assessed the acetylation
state at multiple sites on the four core histones in 7 PD
and 7 control samples showing a prominent difference
in the pan-acetylation analysis (Fig. 1b, Supplementary
Table S1). The acetylated fraction of each histone site
and the total histone quantity were analyzed using linear
mixed models with gender, age and PMI as fixed effects
and subject and blot number as random effects. These
analyses indicated a significant increase in H2BK15ac
(p = 1.4 × 10− 5), H3K9/14 ac (p = 3.9 × 10− 4), H3K27ac
(p = 4.5 × 10− 8), H3K56ac (p = 0.01) and H4K12ac (p =
5.0 × 10− 3) in PD. No significant difference was found
for H2AK5, H4K5, H4K16 or α-tubulin, used as a non-
histone control (Fig. 1b-c, Supplementary Table S2). In
addition, we found increase in the total quantity of the
four histone proteins (H2A: p = 2.7 × 10− 5, H2B: p =
1.1 × 10− 8, H3: p = 2.0 × 10− 7; H4: p = 3.9 × 10− 18).
To control that our findings were not driven by differ-
ences in cell type composition, we carried out immuno-
blot analyses of protein markers for neurons (NeuN),
astrocytes (GFAP), oligodendrocytes (CNP1), microglia
(CX3CR1) and total number of nuclei (NUP188), in the
same samples used for acetylation assessment. Statistical
analyses of these data indicated increase in CNP1 (p =
3.9 × 10− 5, Fig. 1d, Supplementary Table S2), but no
changes in the other markers. We thus repeated the his-
tone acetylation analyses adding CNP1 as a covariate to
the statistical model. As shown in Supplementary Table
S2, all of the indicated hyperacetylated sites remained
significant after CNP1 adjustment.
Similar to findings from PFC, H3K27 hyperacetylation
was also observed in the PD striatum (p = 0.034) and
cerebellum (p = 0.016), areas typically spared by neuronal
loss [2], but exhibiting disease-related pathology, includ-
ing Lewy pathology [36, 37] and mitochondrial respira-
tory deficiency [38] (Fig. 2, Supplementary Table S2).
Histone hyperacetylation in the PD brain is accompanied
by upregulation of sirtuin protein levels
Histone hyperacetylation can be induced by mitochon-
drial respiratory complex-I deficiency [10, 39, 40], a
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Fig. 1 Hyperacetylation of multiple histone sites in the PD prefrontal cortex. Representative Western blots and the ratios of their quantified
densitometric measurements of the indicated proteins (or their modifications) in individuals with PD (orange) and controls (blue) are shown.
GAPDH served as loading control. Values were rescaled [0,1]. Boxplots show the mean of replicates for each individual. The indicated p-values are
based on a linear mixed model (see Methods). a Global protein acetylation detected by a pan-acetyl lysine antibody. b Relative acetylation of
histone lysine residues and quantification of the total histone proteins. c Relative acetylation of α-tubulin on lysine K40. d Immunodetection and
densitometric quantification of relative protein levels of the nuclear marker (NUP188) and cell type-specific marker proteins: NeuN – neurons,
GFAP – astrocytes, CNP1 – oligodendrocytes, CX3CR1 - microglia
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pathological feature found throughout the PD brain, in-
cluding the PFC, striatum and cerebellum [38]. This ef-
fect is thought to be mediated by decreased NAD+/
NADH ratio, attenuating the activity of NAD+-
dependent class III histone deacetylases known as sir-
tuins [39, 41–44]. Direct confirmation of this mech-
anism in our samples would require a reliable
determination of their intracellular NAD+, which was
not feasible due to rapid postmortem degradation
[45]. However, it was previously reported that de-
creased sirtuin activity caused by NAD+ deficiency is
accompanied by increased protein quantity [46, 47].
Thus, we assessed the protein levels of SIRT1, SIRT2
and SIRT3, localized to the nucleus, cytosol and
mitochondria, respectively, as surrogates for their ac-
tivity. We were specifically interested in these pro-
teins, because they have been linked to aging and
neurodegeneration [41]. Immunoblot analyses of the
14 samples assessed for histone acetylation, indicated
a significant upregulation of SIRT1 (p = 2.0 × 10− 3)
and SIRT3 (p = 3.0 × 10− 3) in PD. No difference was
detected for SIRT2 (Fig. 2c, Supplementary Table S2),
in line with the unaltered acetylation state of its tar-
get, α-tubulin (Fig. 1c). Moreover, treatment of SH-
SY5Y cells with the sirtuin inhibitor sirtinol led to a
substantial hyperacetylation of H3K27, in comparison
to control cells (Fig. 2d), indicating that sirtuins can
indeed modulate the acetylation of this residue.
Fig. 2 Altered H3 acetylation occurs in multiple brain regions, is accompanied by sirtuin upregulation and is not induced by anti-Parkinson drugs
in-vitro. a-c Representative Western blots and quantification plots showing the ratios of quantified densitometric measurements of the indicated
proteins in individuals with PD (orange) and controls (blue). GAPDH and β-tubulin serve as loading controls. Values were rescaled [0,1]. Boxplots
show the mean of replicates for each individual. The indicated p-values are based on a linear mixed model (see Methods). a, b Acetylated H3K9/
14 and H3K27 and total histone protein H3 levels in the cerebellum (a) and striatum (b) from individuals with PD and controls. c Sirtuin proteins
in the prefrontal cortex of PD and controls. d Acetylated H3K27 in SH-SY5Y cells, untreated (UT) or treated with different concentrations of the
sirtuin inhibitor Sirtinol, or the solvent (DMSO) for 6 h. A representative blot is shown. Boxplots show the quantified ratios of three biological
replicates (indicated in different colors) carried out in duplicates, rescaled [0,1]. e Acetylated H3K9/14, H3K27 and total H3 protein in differentiated
SH-SY5Y-derived dopaminergic neuron-like cells treated with the histone deacetylase inhibitor Trichostatin A (TSA) or anti-Parkinson drugs used
by the PW patients during their last year of life. The numbers indicate the concentration (in μM) of the drug. Carb: Carbidopa; Enta: Entacapone;
Ropi: Ropinirole; DOPA: L-Dopa. UT: untreated control. A representative blot is shown. Bar plots show the mean quantified ratios of three
biological replicates (rescaled [0,1]). Dots indicate the values of each of the individual replicates
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Histone hyperacetylation is not induced by anti-Parkinson
drugs in cellulo
We next investigated whether the observed altered his-
tone acetylation in PD could result from treatment with
anti-Parkinson agents. To test this, we exposed fully dif-
ferentiated SH-SY5Y cells to the drugs used by most in-
dividuals with PD from the PW cohort during their last
year of life (L-DOPA, carbidopa, entacapone and ropi-
nirole), and monitored acetylation of H3K9/14 and
H3K27 by immunoblot (Supplementary methods). These
analyses indicated no effect for any of the tested anti-
Parkinson drugs on histone acetylation in our model
(Fig. 2e). Nevertheless, these findings cannot completely
rule out the possibility that altered histone acetylation
can be, at least partially, induced by drug-related effects
in the human brain over a prolonged period of time.
Acetylated H3K27 exhibits higher genomic occupancy in
PD
We next carried out ChIP-seq analysis of acetylated
H3K27 (H3K27ac) in all PFC samples from the PW co-
hort (n = 28), Supplementary Table S1). First, we charac-
terized the genomic distribution of H3K27ac in the PD
and control groups. For this purpose, we identified
H3K27ac enriched genomic regions (peaks) in each
group separately (see Methods). In line with the in-
creased H3K27ac signal observed in the immunoblot
analysis, a higher number of peaks (146,763 vs. 135,662),
as well as a higher proportion of group-unique peaks
(32.2% vs. 13.2%), and wider genome coverage (10.6% vs.
9.11%) were found in the PD- compared to the control
group (Fig. 3a, Supplementary Table S3). We then com-
pared the distribution of genomic annotations and de-
tection p-values of overlapping and unique peaks
between the PD and control groups. In both groups,
unique peaks occurred more frequently in intergenic
and intronic regions than in promoter and exonic re-
gions (Supplementary Fig. S1a, b). Since unique peaks
were also characterized by significantly higher detection
p-values, compared to the overlapping peaks (Fig. S1c,
d), we believe that most of these represent “noisy”
H3K27 acetylation.
ChIP-seq data corroborates H3K27 hyperacetylation in the
PD brain
Next, we redefined H3K27ac peaks by identifying
H3K27ac enriched regions by aggregating all PW sam-
ples (see Methods). The final peak-set consisted of 160,
521 peaks, covering 11.6% of the genome and distributed
over all 22 autosomes and both sex chromosomes (me-
dian peak size, 817 bp, Fig. 3d). All downstream analyses
were performed based on this peak-set, henceforth re-
ferred to as PW_peak-set.
ChIP-seq data reflects the abundance and genomic
distribution of the target protein (or protein modifica-
tion) which can vary substantially between samples [48].
Based on the observed increase in H3K27ac fraction in
the immunoblot analysis, we anticipated an increase in
overall H3K27ac ChIP-seq signal in PD. Thus, we rea-
soned that the most suitable approach for normalization
of our data would be using reads in peaks (RiP) anno-
tated to house-keeping genes, as previously proposed
[48]. We modified this approach by manually selecting
peaks annotated to known housekeeping genes that ex-
hibit a saturated peak signal covering most of the gene
body (Supplementary Fig. S2). The rationale here was
that these genes should be saturated with histone acetyl-
ation and are, therefore, expected to exhibit little bio-
logical variation.
To validate our normalization approach, we performed
additional H3K27ac immunoblot and ChIP-seq analyses
in samples from 55 individuals (including the study sub-
jects, Supplementary Table S1) and tested the correl-
ation between the immunoblot and ChIP-seq data
normalized by different approaches. As shown in Sup-
plementary Fig. S3, the highest correlation between im-
munoblotting and ChIP-seq data was observed when the
total number of RiP was normalized to our manually
chosen peaks. Importantly, comparison of normalized
RiP between PD and control samples corroborated the
finding of general H3K27 hyperacetylation in PD (Sup-
plementary Fig. S3).
Cell composition is a major source of variation in bulk
tissue H3K27ac ChIP-seq data
Since different cell-types exhibit distinct epigenetic land-
scapes [19], bulk tissue data must be evaluated in the
context of the underlying cellular composition [22, 49,
50]. To estimate the cellular composition in our ChIP-
seq data, we used an approach similar to the one de-
scribed by Mancarci et al. [22]. Briefly, we intersected
genomic H3K27ac binding sites differentiating between
NeuN-positive and NeuN-negative brain cells [19] with
the list of brain cell-type specific marker-genes [22], in
order to obtain genomic H3K27ac cell-type marker sites.
The first principal component of reads aligned to the
marker sites was used to obtain Marker Site Profiles
(MSPs) and was used as a proxy for the relative abun-
dance of the corresponding cell-types across the sam-
ples. We validated this approach in publicly available
ChIP-seq data from cortical and cerebellar bulk tissue
samples [51], and ChIP-seq data from entorhinal cortex
of individuals with Alzheimer’s disease and healthy con-
trols [8]. MSP analysis of these data successfully recapit-
ulated the well-known increased abundance of glial cells
in cortical vs cerebellar samples [52, 53], and decreased
number of neurons in the entorhinal cortex of subjects
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with Alzheimer’s disease compared to controls [54, 55]
(Supplementary Fig. S4a, b).
Next, we performed MSP analysis in the PW_peak-set
data. This analysis indicated no significant differences in
cell-type abundance between the PD and control groups
(Supplementary Fig. S5). Nevertheless, since the cellular
composition of cortical samples can be affected by vari-
able white matter contamination introduced during dis-
section [28], we assessed the effect of oligodendrocyte
MSPs and other experimental and demographic covari-
ates on the ChIP-seq data. Sample-to-sample correlation
indicated that the samples clustered mainly based on
oligodendrocyte MSPs (Fig. 3b). Accordingly, the first
principal component of the data was mostly associated
with oligodendrocyte MSP (Supplementary Fig. S6),
confirming that oligodendrocyte composition is a major
source of variance in our data. Therefore, oligodendro-
cyte MSPs were accounted for in all downstream
analyses.
Hyperacetylation of H3K27 in the PD brain is a genome-
wide phenomenon
We next sought to identify differentially acetylated re-
gions (DARs) for H3K27 between PD and control sam-
ples. After filtering (see Methods), 133,716 peaks
annotated to 17,182 genes remained for downstream
analyses. Five samples (one control and four PD sam-
ples) were detected as outliers and excluded from differ-
ential peak analysis (Supplementary Table S1).
Differential peak analysis was performed using the
Fig. 3 H3K27ac ChIP-seq analysis of PD and control samples. a Different peak-sets used for the different stages of ChIP-seq analysis. Shown, as an
example, is a genomic region around the oligodendrocyte marker MBP. Peaks annotated to this region, in each peak-set are shown by colored
boxes. The CellType_peak-set was used for the MSP calculation. Group specific peak-sets were used to characterize the distribution of H3K27ac
bound regions in cases and controls. Barplots show the comparison between the two groups (Supplementary Table S3). PD group exhibited
higher number of peaks, higher percentage of unique peaks and higher percentage of genomic coverage, consistent with genome-wide H3K27
hyperacetylation. The PW_peak-set was used for the differential peak analysis. Shown are group overlays of sample fold of change compared to
input control. b Hierarchical clustering of the samples indicated that samples cluster based on their cellular composition. Supplementary Fig. S6
shows the association of each of the variables with the main principal components of the data. c MA plot based on the PW_peak-set indicates
that increased H3K27ac in PD is observed genome-wide, rather than being restricted to specific regions. d Manhattan plot showing the
distribution of genomic locations and differential p-values of the H3K27ac PW_peak-set. The red dashed line indicates the -log10 of the highest
p-value with < 5% false positive rate (Benjamini-Hochberg adjusted p-value < 0.05). Corresponding plots for the NBB cohort are shown in
Supplementary Fig. S5
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“DESeq2” R package, adjusting for age, sex, batch, PMI,
oligodendrocyte MSP and normalization peak ratio.
DARs were defined as differentially acetylated peaks with
adjusted p-value < 0.05.
Our analysis identified 2877 hyperacetylated and only
14 hypoacetylated PD-associated DARs, annotated to
1434 and 9 genes, respectively. The top-ranked hypera-
cetylated and hypoacetylated DARs resided within the
DLG2 (adjusted p = 9.8 × 10− 4) and PTPRH (adjusted p-
value 9.0 × 10− 3) genes, respectively, both of which have
been previously associated with PD [4, 56–58]. The full
list of DARs with their annotated genes is provided in
Supplementary Table S4. An MA-plot (the log ratio vs.
mean count) of all regions included in the analysis indi-
cated a genome-wide trend for H3K27 hyperacetylation
in PD (Fig. 3c).
H3K27 hyperacetylation in the PD cortex is replicated in
an independent cohort
To validate our findings, we carried out ChIP-seq in an
independent cohort from the Netherlands Brain Bank
(NBB, Supplementary Table S1). In agreement with our
finding from the PW cohort, we observed an increase in
the percentage of unique peaks as well as increased total
genomic coverage in the PD group (Supplementary
Table S3). The distribution of genomic annotations
among the unique and overlapping peaks and the distri-
bution of peak p-values were similar between the two
cohorts (Supplementary Fig. S1). As in the PW cohort,
cellular composition accounted for most of the interindi-
vidual variance in this cohort (Supplementary Fig. S6b,
S7a).
Differential acetylation analysis corroborated the find-
ing of PD-associated genome-wide H3K27 hyperacetyla-
tion observed in the PW cohort (Supplementary Fig.
S5b). In total, the analysis identified 2486 hyperacety-
lated DARs, mapped to 946 genes, and 227 hypoacety-
lated DARs, mapped to 253 genes (Supplementary Table
S5). Strikingly, 275 out of the 946 genes with hyperacety-
lated DARs and 2 out of 253 genes with hypoacetylated
DARs replicated across both cohorts (Fig. 4c, hypergeo-
metric test: p = 2.49 × 10− 85 and p = 8.2 × 10− 3, respect-
ively). These 277 genes are henceforth referred to as
“replicated genes”. The top replicated genes (ranked
Fig. 4 Replicated genes and replicated DARs. a, b Schematic representation of two levels of replication between the PW and NBB cohorts.
H3K27ac peaks are illustrated by colored lines, representing control (blue) and PD (orange) samples, with the height of the peak representing the
peak intensity. Shown is a hypothetical gene X, with exons represented as grey boxes and introns represented by lines. In both cases, the gene
has two pairs of common peaks: Peak_a/A, mapped to the first exon of the gene and Peak_b/B, mapped to the third exon of the gene. a Altered
H3K27 acetylation occurs at different regions of gene X in each cohort. Thus, while gene X harbors altered H3K27 acetylation in both cohorts (i.e.
gene X is a replicated gene), it does not harbor replicated DARs. b Altered H3K27 acetylation occurs at the same region of gene X in both
cohorts. In this case, gene X is a replicated gene with a replicated DAR. c Venn diagram showing the number of replicated genes (with or
without replicated DARs) between the two cohorts, out of all genes represented in our ChIP-seq data from both cohorts. d Venn diagrams
showing the number of replicated DARs between the two cohorts, out of all common peak pairs (left) and their corresponding annotated genes
(right). e Venn diagram showing the overlap of PD-implicated genes with DARs between cohorts. All DARs exhibited hyperacetylation. f Venn
diagram showing the number of PD-implicated genes with adjusted metaP < 0.05
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based on their adjusted p-value in the PW cohort) are
shown in Table 1 and a complete list is provided in Sup-
plementary Table S6.
Meta-analysis of ChIP-seq data from PW and NBB cohorts
In order to perform meta-analysis of the ChIP-seq data
we first harmonized the data from the two cohorts by
pairing peaks with the same structural and functional
genomic annotation (e.g. promoter, exon, UTR). These
peaks are henceforth referred to as “common peaks”. For
each common peak pair, we then calculated the Fisher’s
meta p-value (metaP). A toy example of a common peak
pair is shown in Fig. 4a, b.
In total, the harmonization process resulted in 52,286
pairs of common peaks. Out of these, 7288 (mapped to
2972 genes) had adjusted metaP < 0.05 (Supplementary
Table S7, Fig. 4d, f). Moreover, 300 pairs represented
peaks defined as DARs in both cohorts (Fig. 4d, hyper-
geometric p-value = 5.29 × 10− 37). These 300 common
peak pairs, mapped to 197 genes, are henceforth referred
to as “replicated DARs”. Nearly all (295/300) replicated
DARs were hyperacetylated in both cohorts and only a
single DAR, mapped to the PTPRH gene, was hypoacety-
lated. Genes annotated to the top replicated DARs,
ranked based on their adjusted metaP, are provided in
Table 2.
Altered H3K27 acetylation has a predilection for genes
with an established link to PD
We next wondered whether genes with an established
involvement in PD are over-represented among DAR-
harboring genes. To assess this, we compiled a list of
genes that fulfilled at least one of the following criteria:
(a) are associated with PD based on the most recent and
largest GWAS meta-analysis [4], (b) are implicated in
monogenic PD [59, 60], or (c) encode proteins with a
central role in PD-related neuropathology [2, 61, 62].
Among the 92 genes meeting these criteria (Supplemen-
tary Table S8), 83 could be assessed in ChIP-seq data
from both cohorts and are henceforth referred to as
“PD-implicated genes”. Out of these, six genes: DLG2,
MAP 4 K4, CRHR1, MBNL2, SH3GL2 and APP, har-
bored DARs in both cohorts (hypergeometric p-value =
2.9 × 10− 3, Fig. 4e). In addition, 24/83 PD-implicated
genes had adjusted metaP < 0.05 (hypergeometric p-
value = 6.9 × 10− 3, Supplementary Table S8, Fig. 4f).
These included genes with key-roles in the pathogenesis
of idiopathic and/or monogenic PD: SNCA, MAPT, APP,
PRKN and PARK7. Interestingly, the significantly hyper-
acetylated peak in SNCA was in an enhancer region of
the gene previously shown to be affected by both genetic
variation [63] and drug exposure associated with PD
[64] (Fig. 5a).
H3K27 hyperacetylated regions are associated with an
increased ratio of p300 binding sites relative to non-
SIRT1 HDAC binding sites
Our immunoblot analyses suggested that H3K27 hypera-
cetylation may be accompanied by decreased sirtuin ac-
tivity, primarily SIRT1. It is well established that SIRT1
can also deacetylate and thus suppresses the activity of
the histone acetyl transferase p300 [65], the primary me-
diator of H3K27 acetylation [66]. Thus, we reasoned that
if H3K27 hyperacetylation in PD is indeed mediated by
decreased SIRT1 activity, it should be associated with re-
gions exhibiting increased binding of p300 and de-
creased binding of non-SIRT1 HDACs. To test this, we
integrated our data with the relevant ChIP-seq data de-
rived from the ENCODE project [23] (see Methods).
Specifically, we quantified the number of p300 bound re-
gions (p300_binding) or non-SIRT1 HDAC bound re-
gions (HDAC_binding) from ENCODE that overlap with
H3K27ac peaks in our data and assessed the association
of the two measures with H3K27 hyperacetylation level
of each region. In both cohorts, the ratio of p300 binding
sites over non-SIRT1 HDAC binding sites was signifi-
cantly higher in regions overlapping with hyperacety-
lated DARs compared to non-DARs (Fig. 5c) . Notably,
this was also true when restricting the analyses to the
PD-implicated genes (Fig. 5d). Linear model analysis
showed positive association of H3K27 hyperacetylation
Table 1 Top replicated genes between PW and NBB cohorts
GeneSymbol log2(FC)_PW padj_PW log2(FC)_NBB padj_NBB
Hypoacetylated genes
PTPRH −0.81 9.1E-03 −0.94 0.03
JUP −0.43 0.05 −0.44 0.02
Hyperacetylated genes
DLG2 0.68 9.8E-04 0.77 2.0E-03
TNRC6B 0.74 9.8E-04 0.9 0.03
SIK3 0.66 3.2E-03 0.52 0.01
SGK1 0.65 3.2E-03 0.72 0.01
PPP2R2B 1.3 3.5E-03 0.7 8.0E-03
FCHSD2 0.83 3.5E-03 1 0.01
CTNND2 0.52 3.5E-03 0.63 0.01
PTK2 0.71 3.5E-03 0.55 0.02
SLCO1A2 0.58 3.5E-03 0.68 0.02
LPAR1 0.99 3.5E-03 0.55 0.04
FRMD4B 0.64 3.5E-03 0.53 0.04
RNF216 0.6 5.1E-03 0.59 2.3E-03
TMEM132B 0.88 5.1E-03 0.59 0.02
PIP4K2A 0.57 5.1E-03 0.52 0.03
MAP7 0.55 5.9E-03 0.52 0.04
PDE4B 0.59 6.5E-03 0.67 2.4E-03
FRMD5 0.55 6.5E-03 0.67 0.01
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with p300_binding (PW: β = 0.02, p < 2 × 10− 15; NBB:
β = 0.09, p < 10− 26) and negative association with
HDAC_binding (PW: β = − 0.07, p < 10− 26; NBB: β = −
0.14, p < 10− 26). Similar results were obtained when
peaks were collapsed to a gene level (Supplementary
Table S9).
Differential H3K27 acetylation is associated with effective
gene length
We noted that many of the genes with DARs, including
PD-implicated genes, are among the longest in the gen-
ome. We reasoned that this may be because longer
genes have higher histone binding capacity and therefore
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For hyperacetylated regions, the top 15 genes with DARs common to the two cohorts and common DARs in genes previously associated with PD are shown. The
genes were ranked based on Fisher’s meta p-value. The full list of genes is provided in Supplementary Table S6
aPrevious association with PD based on GWAS; Region Location – genomic location (on the indicated chromosome) of the annotated region; Peak location –
genomic location of the relevant peak from each cohort (upper – PW, lower - NBB); LFC – log fold change compared to controls; Peak Name – the peak identifier
in each cohort; Proportion significance – DARs/total common regions annotated to the gene; p- peaks annotated to promoter region of the gene
Toker et al. Molecular Neurodegeneration           (2021) 16:31 Page 12 of 20
are more likely to show a differential signal in the event
of a generalized, unspecific H3K27 hyperacetylation. To
test this hypothesis and ensure that the over-
representation of PD-implicated genes among DAR-
harboring genes is not driven by longer gene length, we
used linear models to assess whether H3K27ac, defined
as -log10(metaP), is associated with PD-implicated genes
while accounting for the effective gene length (EGL), de-
fined as the total length of all regions annotated to a
gene (see Methods). The total number of common re-
gions in a gene was included as a covariate in the model.
For hyperacetylated regions, this analysis indicated a
Fig. 5 H3K27 acetylation is associated with the relative proportion of p300 and non-SIRT1 HDAC binding and overrepresented in PD-implicated
genes. a, b Examples of two PD_implicated genes, SNCA (a) and VPS35 (b). SNCA harbors a DAR (Peak_35531/27168 in PW/NBB respectively) in an
enhancer element whose H3K27 acetylation status is associated with both genetic variation (SNP rs356168) and drugs influencing the risk of PD.
VPS35 does not exhibit DARs in our data. Purple bars indicate H3K27ac peaks in the PW and NBB peaksets. H3K27ac ChIP-seq data from ENCODE
is shown for reference. Pink, blue and yellow bars indicate the binding sites of p300, HDAC1 and HDAC2 respectively, based on ENCODE ChiP-seq
data wgEncodeRegTfbsClusteredV3.bed. c, d Difference in the relative number of p300 and non-SIRT1 HDAC bindings sites between significantly
hyperacetylated and non-significantly hyperacetylated peaks for all (c, Kolmogorov–Smirnov test) or only PD_implicated (d, two-sided Wilcoxon
rank sum test) genes. e Hyperacetylated – regions showing hyperacetylation in both cohorts; Mixed – regions with opposite acetylation trends in
the two cohorts. The dashed line represents the -log10 of the highest metaP corresponding to adjusted metaP < 0.05. Multiple common regions
within the same gene are shown. Highlighted are regions identified as DAR in at least one of the cohorts within PD-implicated genes. metaP –
Fisher’s meta-p value of the corresponding two peaks from PW and NBB cohorts. f Association between -log(p) and each of the indicated
covariates based on linear model. Shown are the coefficients and 95% confidence intervals. The results are shown for the common regions
(metaP) and each of the cohorts separately. Peaks annotated to miRNAs and snRNAs were excluded from the analysis. PDgene – a gene is a PD-
implicated gene. EGL – effective gene length. TotalPeaks – total number of common regions or peaks annotated to the gene
Toker et al. Molecular Neurodegeneration           (2021) 16:31 Page 13 of 20
significant positive association between altered acetyl-
ation and PD-implicated genes (p = 1.0 × 10− 7) as well as
EGL (p < 2.0 × 10− 26). For the hypoacetylated regions,
however, the analysis indicated a significant negative as-
sociation with both PD-implicated genes (p < 2.0 ×
10− 26) and EGL (p < 2.0 × 10− 26). Analysis of each co-
hort independently corroborated these findings, al-
though the negative association with PD-implicated
genes for the hypoacetylated regions was only significant
in the NBB cohort (Fig. 5b, Supplementary Table S10).
DARs differ in their GC content and are enriched in
multiple transcription factor motifs
In both cohorts, the hyperacetylated DARs exhibited low
GC content compared to non-differentially acetylated re-
gions, matched for region length (NBB: 44% vs 51%;
PW: 46% vs. 50%, DARs vs. non-DARs, respectively,
Supplementary Fig. S8). The opposite phenomenon was
observed for the hypoacetylated DARs (NBB: 61% vs
51%; PW: 55% vs. 50%, DARs vs. non-DARs, respect-
ively, Supplementary Fig. S8). Similar results were ob-
tained when comparison was performed only for peaks
annotated to either exonic or intronic regions. Motif en-
richment analysis of the hyper- and hypoacetylated
DARs indicated enrichment in multiple TFBMs. For the
hyperacetylated DARs, significant enrichment was found
for 71 and 94 TFBMs, in the PW and NBB cohorts re-
spectively, with 64 TFBMs overlapping between the two
cohorts. For the hypoacetylated DARs, significant en-
richment was found for 3 and 49 TFBMs, in the PW and
NBB cohorts respectively, two of which were enriched in
both (Supplementary Table S11).
Promoter H3K27 acetylation is decoupled from gene
expression in PD
While it is well accepted that modifications of H3K27ac
are predictive of gene expression levels [67], it was previ-
ously shown that widespread histone hyperacetylation
induced by potent HDAC inhibition does not lead to
major changes in gene expression [68, 69]. To investi-
gate whether a similar decoupling occurs in the PD
brain, we analyzed RNA sequencing (RNA-seq) data
from the PFC of the same individuals included in the
ChIP-seq analysis (Supplementary Table 1, Supplemen-
tary Methods). For each gene, we then calculated the
Pearson’s correlation between the level of its expression
and promoter H3K27ac across controls or individuals
with PD.
In the control group from both cohorts, most genes
exhibited the expected positive correlation between pro-
moter H3K27ac and expression. In the PD group, how-
ever, the distribution of correlations was centered closer
to 0, regardless of the absolute correlation threshold
chosen (Fig. 6a-e). The deviation between the two
groups progressively increased as only genes with higher
correlation between promoter H3K27ac and expression
were included in the analysis (Fig. 6b-e). Importantly,
similar results were obtained based on RLE-normalized
ChIP-seq data (Supplementary Fig. S9), indicating that
the observed decreased correlation between H3K27ac
and transcription levels in PD was not driven by the
normalization method. These results suggest that the
coupling between promoter H3K27 acetylation state and
proximal gene transcription is impaired in the PFC of in-
dividuals with PD.
Functional enrichment analysis based on the decoup-
ling level of the genes, indicated that nucleus-encoded
mitochondrial genes are the most decoupled genes in
both cohorts (Supplementary Table S12). Moreover,
closer examination of these genes revealed that most of
them exhibit negative correlation between the expression
level and promoter H3K27 acetylation (Fig. 6f, Supple-
mentary Table S12).
Discussion
Aberrant H3K27ac occurs genome-wide in the PD brain
We report evidence of increased histone acetylation in
the PFC of individuals with PD with the strongest
change observed for H3K27, a marker of active pro-
moters and enhancers with a fundamental role in regu-
lating gene expression [70, 71]. H3K27 hyperacetylation
in PD is supported by multiple levels of evidence in our
study: (a) immunoblot analyses showed a highly signifi-
cant increase in the acetylated fraction of H3K27 across
three brain regions in PD. Importantly, we show that
this is not driven by underlying differences in cell com-
position of the samples and is unlikely to be induced by
anti-Parkinson medication. (b) ChIP-seq analysis, repli-
cated in two independent cohorts, showed that the total
number of peaks, percentage of unique peaks, genome
coverage and the total number of RiPs are all increased
in the PD samples. The analysis further revealed that in-
creased H3K27ac occupancy has a genome-wide distri-
bution. (c) We found a strong association between
differential H3K27 acetylation and the effective length of
the targeted gene. This association was positive for
hyperacetylated regions and negative for hypoacetylated
regions, in line with a hyperacetylation-predisposing cel-
lular environment in PD.
H3K27 hyperacetylation may be induced by altered
sirtuin activity
We hypothesized that H3K27 hyperacetylation in PD
may be mediated by altered sirtuin activity, due to a de-
creased NAD+/NADH ratio [39, 42, 72] resulting from
complex-I deficiency, a pathological hallmark of the PD
brain [38, 73]. Hyperacetylation of several histone sites,
including H3K27, was indeed observed in animal and
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cell studies, following chemical complex-I inhibition
with PD-associated neurotoxins [10, 74]. In line with our
hypothesis, we observed increased levels of SIRT1 and
SIRT3 proteins in PD samples and no change in SIRT2
quantity, or in the acetylation state of its substrate, α-
tubulin. This is consistent with the notion that SIRT1
and SIRT3, but not SIRT2 activity are susceptible to
changes in physiological NAD+ concentrations [72]. In
line with our findings, reduced sirtuin activity accom-
panied by increase in their protein levels was reported in
Fig. 6 Decreased correlation between promoter H3K27 acetylation state and gene expression in PD Pearson’s correlation between the adjusted
promoter H3K27ac counts and the adjusted RNA-seq counts was calculated for each gene across control or PD subjects in each cohort
separately. a Representative scatter plots showing the adjusted promoter H3K27ac counts (X-axis), the adjusted RNA-seq counts (Y-axis) and the
calculated Pearson’s correlation for three genes: MED13, PTPRH and DLG2 in control (blue) or PD (orange) individuals from the PW or NBB cohorts.
Each dot represents an individual. Cor - Pearson’s correlation. b-e The distribution of correlations for all compatible genes was compared
between the groups for various thresholds of minimal absolute correlation in either of the groups. Results are shown for PW (b, c) and NBB (d, e)
cohorts. The number of genes that remained after applying the correlation threshold is shown in parentheses. The correlations remained closely
distributed around 0 in PD subjects from both cohorts, regardless of the correlation threshold. c, e Median correlations in each group and the
calculated Wilcoxon’s delta shift for the different correlation thresholds. f Nucleus-encoded mitochondrial genes exhibit negative correlation
between promoter H3K27 acetylation and gene expression. Shown are examples for three mitochondria related GO terms
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iPSC-derived dopaminergic cells carrying a LRRK2 mu-
tation [75]. Moreover, complex-I deficiency, decreased
NAD+/NADH ratio, decreased sirtuin activity (accom-
panied by increased protein levels), and increased his-
tone acetylation have all been shown to occur with aging
[5, 41, 44, 46, 47], which is the strongest known risk fac-
tor for PD.
The putative role of SIRT1 in mediating H3K27 hyper-
acetylation in PD is further supported by the observation
that hyperacetylation is more pronounced among re-
gions with high p300/non-SIRT1 HDAC binding site ra-
tio. This is because decreased SIRT1 activity increases
p300-mediated H3K27 acetylation, and can be compen-
sated by other HDACs. Namely, H3K27 hyperacetylation
induced by decreased SIRT1 activity is expected be more
pronounced in regions exhibiting multiple p300 binding
sites and fewer non-SIRT1 HDAC binding sites. While
our findings strongly suggest the sirtuins may be in-
volved in H3K27 hyperacetylation in PD, further studies
are required to validate this effect, and to establish
whether this involvement is direct (i.e. by deacetylation
of H3K27) or indirect (e.g., via reduced deacetylation
and thereby activation of p300).
H3K27 hyperacetylation is over-represented in PD-
implicated genes
While H3K27 hyperacetylation appears to be a genome-
wide phenomenon in the PD brain, it also shows a
highly significant predilection for genes implicated in
PD. Meta-analysis of our two cohorts identified H3K27
hyperacetylated regions in 24/83 genes linked to idio-
pathic and/or monogenic forms of PD (Supplementary
Table S8). These include 21 genes associated with PD by
GWAS [4], genes encoding proteins involved in PD
pathology (SNCA, MAPT, APP) [2, 61, 62] and genes in
which mutations cause Mendelian PD (SNCA, PRKN,
PARK7) [76, 77]. In addition, H3K27 hyperacetylation
was observed in genes associated with more complex
forms of parkinsonism and/or vulnerability to PD-
related pathology such as FBOX7 [78] and POLG [59].
Several mechanisms may underlie the observed over-
representation of PD-implicated genes. First, it is plaus-
ible that H3K27 acetylation at promoter and/or enhan-
cer regions of these genes is modulated by genetic
variation and/or environmental factors associated with
PD. For instance, the H3K27 acetylation state of the
SNCA enhancer region, significantly hyperacetylated in
our data, was shown to be affected by both genetic vari-
ation [63] and drug exposure associated with PD [64].
Second, it is likely that pathogenic processes involved in
PD induce the expression of genes implicated in the dis-
ease. For example, the expression levels of PRKN and
PARK7 increase in response to oxidative stress [79–82].
Since, the regulation of transcription often involves
histone acetylation, impairment of the deacetylation ma-
chinery, would over time lead to excessive H3K27 acetyl-
ation of these genes. Finally, by relaxing chromatin
structure, H3K27 hyperacetylation in genomic regions
associated with PD, predisposes these areas to somatic
mutations, including genomic rearrangements [83]. As
previously suggested [84], this could act synergistically
with other predisposing factors, such as age and oxida-
tive injury, eventually leading to PD-specific pathology.
H3K27 hypoacetylation in the PTPRH gene may
contribute to PD pathophysiology
Considering the general H3K27 hyperacetylation in the
PD brain, the robust hypoacetylation of H3K27 in the
PTPRH gene, encoding protein tyrosine phosphatase re-
ceptor type H, is of particular interest. While little is
known about the physiological function of PTPRH, it
was previously found to be enriched in loss-of-function
mutations in PD [57]. Furthermore, it was shown that
RNAi-mediated downregulation of the PTPRH homolog
in Drosophila enhances α-synuclein neurotoxicity [57].
Our finding of selective H3K27 hypoacetylation of the
PTPRH region in PD, corroborates the hypothesis that
decreased function of this gene may contribute to the
pathophysiology of PD. Additional studies are required
to establish the physiological function of PTPRH and its
involvement in the pathophysiology of PD.
Differential H3K27ac is associated with GC content
The observation that hyperacetylated DARs exhibit low
GC content, whereas hypoacetylated DARS exhibit high
GC content, is intriguing. While the reason behind this
phenomenon is unclear, the existence of enhancers with
high and low GC content was previously described, link-
ing low GC content-enhancers to the immune response
[85]. Additional studies are required to understand the
mechanism underlying the selectivity of differential
H3K27ac towards different sequence composition and
its link to PD.
Decoupling between promoter H3K27 acetylation and
gene expression in the PD brain
The attenuated correlation between promoter H3K27
acetylation and gene expression is intriguing, since it in-
dicates that a fundamental mechanism of gene regula-
tion is defective in the PD brain. A plausible explanation
for this phenomenon is a global hyperacetylation of en-
hancer regions, compromising the regulation of gene ex-
pression. Indeed, in both cohorts, about half of the
identified H3K27ac peaks as well as DARs were anno-
tated to non-coding regions. Furthermore, since histone
acetylation is tightly linked to the metabolic state of the
cell [72], this decoupling suggests that cellular responses
to metabolic stress may be severely compromised in PD.
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This putative compromised response to metabolic stress
is further supported by the finding that, in both cohorts,
the highest degree of decoupling is observed among
nuclear-encoded mitochondrial genes. Moreover, the
negative correlation between H3K27 acetylation and
gene expression of these genes supports the involvement
of sirtuins, in particular SIRT1, in the pathophysiology
of PD. This is because in addition to histones, SIRT1
deacetylates and activates PGC-1α, the key regulator of
mitochondrial biogenesis [42, 72, 86]. Thus, decreased
SIRT1 activity would simultaneously lead to increased
histone acetylation and reduced expression of nuclear-
encoded mitochondrial genes, resulting in negative cor-
relation between their expression level and promoter
H3K27 acetylation state. Moreover, decreased expression
of mitochondrial genes would initiate a vicious circle by
decreasing NAD+/NADH ratio and further reducing
SIRT1 activity.
Conclusions
We show that H3K27 acetylation, a fundamental mech-
anism modulating gene expression, is severely dysregu-
lated in the PFC of individuals with idiopathic PD. The
highly significant concordance between the two cohorts
and the clear predilection for genes strongly linked to
PD, validate our findings and suggest that epigenetic
dysregulation plays an important role in the pathogen-
esis of the disease. Importantly, since histone acetylation
and NAD metabolism can be pharmaceutically modu-
lated, our results open the possibility that agents target-
ing these biological processes may have therapeutic
potential for PD and should be further explored.
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